NCT01810770 is a Phase 3 clinical trial of Radium-223 dichloride (Xofigo, BAY88-8223) in Prostatic Neoplasms, sponsored by Bayer.

Who is sponsoring NCT01810770?

NCT01810770 is sponsored by Bayer.

What drugs are being tested in NCT01810770?

Interventions in NCT01810770: Radium-223 dichloride (Xofigo, BAY88-8223).

What condition does NCT01810770 study?

NCT01810770 studies Prostatic Neoplasms.

Is NCT01810770 still recruiting?

NCT01810770 is currently completed. Last updated 19 September 2018.

Last reviewed 2018-09-19 · How we verify

NCT01810770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Completed Phase 3 Last updated 19 September 2018

What this trial tests

Phase 3 trial testing Radium-223 dichloride (Xofigo, BAY88-8223) in Prostatic Neoplasms in 243 participants. Completed in 25 September 2017.

Timeline

26 March 2013

Primary endpoint
25 September 2017

25 September 2017

Quick facts

Lead sponsor	Bayer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	243
Start date	26 March 2013
Primary completion	25 September 2017
Estimated completion	25 September 2017
Sites	27 locations across China, Taiwan, Singapore, South Korea

Drugs / interventions tested

Radium-223 dichloride (Xofigo, BAY88-8223) — full drug profile →

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →

Sponsor

Bayer — full company profile →

Who can join

18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy (Overall survival \[OS\]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Radium-223 dichloride (Xofigo, BAY88-8223)

Trials testing the same drug.

NCT05301062 — A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Ad · terminated
NCT04521361 — A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones · Phase 1 · completed
NCT04597125 — RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhi · Phase 4 · active not recruiting
NCT04516161 — EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Sur · completed
NCT04232761 — Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, W · completed

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01810770 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 19 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01810770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing